Fundraising FoxAngenMed
1 known investors
Find your way into AngenMed
Sign up to see every warm intro you have to AngenMed
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AngenMed team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AngenMed develops neoantigen-targeting cell-based cancer immunotherapies, including dendritic cell vaccines and neoantigen-specific T cell products personalized to each patient's tumor mutations. The company operates in the biotech and cancer therapeutics space, using tumor sequencing to identify neoantigens and manufacture DC and T-cell products.
Investors · 1
Frequently asked questions
- What does AngenMed do?
- AngenMed develops neoantigen-targeting cell-based cancer immunotherapies, including dendritic cell vaccines and neoantigen-specific T cell products personalized to each patient's tumor mutations. The company operates in the biotech and cancer therapeutics space, using tumor sequencing to identify neoantigens and manufacture DC and T-cell products.
- Who are AngenMed's investors?
- AngenMed's investors include Maxpro Ventures.